Cineplex: Canaccord Lifts Price Target To $18 On Improving Outlook

On May 13, Cineplex Inc. (TSX: CGX) reported its first quarter financial results. The company announced revenues of $228.7 million, up 452% from its 2021 pandemic results. The company saw its net loss get cut in half year over year, going from $89.7 million in 2021 to $42.2 million in 2022. Additionally, the company reported a positive adjusted EBITDA of $36.5 million.

Cineplex reported box office revenues of $79.95 million, while foodservice revenues grew to $68.34 million. Amusement revenues grew to $50.4 million for the quarter and all other revenues came in at $14.4 million for the quarter.

The company reported 6.7 million people attended their theatres this quarter, compared to the 0.4 million last year. This means that the box office revenue per patron grew from $9.20 last year to $12.00 this year. This was similar to its concession revenues per patron, which grew 44% year over year to $8.82.

Cineplex currently has 6 analysts covering the stock with an average 12-month price target of C$17.75, or an upside of 43%. Out of the 6 analysts, 1 has a strong buy rating, 3 analysts have buy ratings and the last 2 analysts have hold ratings.

In Canaccord Genuity’s note on the results, they reiterate their speculative buy rating and increase their 12-month price target from C$17 to C$18, saying that the box office outlook continues to improve.

Canaccord says that Cineplex box office results came in slightly below their estimates while total revenues beat their estimates. Cineplex’s revenue of $228.7 million beat their estimate of $194.9 million, the beat was primarily driven by “a robust performance in LBE and P1AG.” Though the company’s adjusted EBITDA was ($5.7) million compared to the ($1) million estimate, which was impacted by additional COVID lockdowns around the world.

On box office revenues, which came in below their $85.9 million estimates, about 51% of pre-pandemic revenues, they say that the ongoing recovery “was impacted by the lockdowns imposed in the latter half of December.” While Canaccord says that attendance and BPP came in roughly in line with their estimates while BPP was a first-quarter record.

Lastly, on the results Canaccord says that there were a few notable things. First was that P1AG continued to show strong growth as it was at 73% of 2019 levels while the company benefitted from reopening locations and prudent cost management. While the company’s media revenues came in below their $18.1 million estimates.

Below you can see Canaccord’s updated estimates on Cineplex.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

The Grocery Grift: Why Toronto and New York Are About to Light Taxpayer Money on Fire

This Gold Story Starts With Cash Flow | Gordon Robb – ESGold

Silverco Cusi Mine PEA: Bigger Isn’t Always Better

Recommended

Antimony Resources Drills 4.38% Sb Over 7.05 Metres At Bald Hill In Final Hole Of 2025 Program

Kirkland Lake Drills 121 Metres Of 1.01 g/t Gold At Mirado

Related News

Cresco Labs: Analysts Raise Targets Following Massachusetts Acquisition

On March 18th, Cresco Labs (CSE: CL) announced the acquisition of Cultivate, a Massachusetts-based vertically...

Tuesday, March 23, 2021, 11:53:00 AM

Aphria: PI Financial Raises Price Target, Canaccord Reiterates Target

Last week, Aphria Inc (TSX: APHA) (NASDAQ: APHA) reported their year-end and fourth-quarter financial statements....

Sunday, August 2, 2020, 01:30:00 PM

Amazon Consensus Price Target Rises Following Strong Earnings

Amazon.com Inc (NASDAQ: AMZN) hit a new high on Friday, getting close to a $2...

Wednesday, May 5, 2021, 10:39:00 AM

BMO Raises Jazz Pharmaceuticals Price Target To US$205

It was announced last week wednesday that Jazz Pharmaceuticals (NASDAQ: JAZZ) would be acquiring GW...

Monday, February 8, 2021, 10:40:00 AM

Paradigm Initiates Coverage On Trulieve With $59 Price Target

Earlier this month, Paradigm Capital initiated coverage on Trulieve Cannabis Corp (CSE: TRUL) with a...

Sunday, December 27, 2020, 01:42:00 PM